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Malignant pleural mesothelioma (MPM) is an aggressive malignancy with
very limited therapeutic options. Fibroblast growth factor (FGF) signals play
important roles in mesothelioma cell growth. Several FGFs and FGF recep-
tors (FGFRs) are predicted targets of the miR-15/16 family, which is down-
regulated in MPM. The aim of this study was to explore the link between the
miR-15/16 family and the FGF axis in MPM. Expression analyses via RT-
qPCR showed downregulation of the FGF axis after transfection with miR-
15/16 mimics. Direct interaction was confirmed by luciferase reporter assays.
Restoration of miR-15/16 led to dose-dependent growth inhibition in MPM
cell lines, which significantly correlated with their sensitivity to FGFR inhibi-
tion. Treatment with recombinant FGF2 prevented growth inhibition and
further reduced the levels of FGF/R-targeting microRNAs, indicating a
vicious cycle between miR-15/16 down- and FGF/FGFR signaling upregula-
tion. Combined inhibition of two independent miR-15/16 targets, the FGF
axis and Bcl-2, resulted in additive or synergistic activity. Our data indicate
that post-transcriptional repression of FGF-mediated signals contributes to
the tumor suppressor function of the microRNA-15/16 family. Inhibiting
hyperactivated FGF signals and Bcl-2 might serve as a novel therapeutic
combination strategy in MPM.
1. Introduction
Malignant pleural mesothelioma (MPM) is a very
aggressive malignancy of the pleural linings with dis-
mal outcome (median survival of 9–17 months) and
limited, mostly palliative therapeutic options (van
Zandwijk et al., 2013). MPM is highly related to
asbestos exposure, and due to the long latency period
and the widespread use of asbestos, the worldwide
incidence is expected to further increase within the
next decades (Linton et al., 2012; Robinson, 2012).
As classical malignant drivers such as mutated
EGFR or Raf are uncommon in MPM, treatments
specifically targeting these mutations are ineffective in
this disease (Dubey et al., 2010; Garland et al., 2007;
Govindan et al., 2005). Instead, genomic analysis has
revealed genetic deletions in MPM largely in genes
considered to be tumor suppressive, such as P16/
CDKN2A and NF2 (Jaurand and Fleury-Feith, 2005),
which are not easily targetable. We and others have
previously identified fibroblast growth factors (FGFs)
and their receptors (FGFRs) as signaling molecules
Abbreviations
FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; MPM, malignant pleural mesothelioma.
58 Molecular Oncology 12 (2018) 58–73 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
being overexpressed and driving malignant growth in
MPM (Marek et al., 2014; Schelch et al., 2014).
Hyperactivation of FGF receptors and downstream
pathways has been associated with tumor progression,
therapy resistance, and poor prognosis (Korc and Frie-
sel, 2009). However, unlike, for instance, FGFR1 in
non-small-cell lung cancer (NSCLC) and squamous
cell lung cancer (Weiss et al., 2010) or FGF19 in hepa-
tocellular carcinoma (HCC) (Sawey et al., 2011),
recurrent gene amplification of FGFs or FGFRs was
not detected in MPM and thus cannot account for the
frequent overexpression of several FGF/R family
members found in MPM (Marek et al., 2014).
MicroRNAs (miRNAs) are small noncoding RNAs
post-transcriptionally regulating gene expression via
interaction with sites in the 30UTRs of target mRNAs
(He and Hannon, 2004). They are known to be impor-
tant regulators of cell signaling proteins during cancer
development and progression (Garzon et al., 2009). In
particular, the miR-15/16 microRNA family that tar-
gets numerous cancer-relevant factors including the
anti-apoptotic protein Bcl-2 has been shown to func-
tion as a tumor suppressor in various tumors (Bandi
et al., 2009; Bhattacharya et al., 2009; Bonci et al.,
2008), and we have shown that this is also the case in
MPM (Reid et al., 2013).
Recently, miR-16 was shown to directly interact
with FGF2 in nasopharyngeal carcinoma (He et al.,
2016), and several other members of the FGF/R fam-
ily are predicted targets of miR-15/16. Here, we experi-
mentally validated the targeting of FGF1, FGF2, and
FGF18 as well as FGFR1 and FGFR4 by the miR-
15/16 family in MPM, suggesting a potential mecha-
nism contributing to the overexpression of the FGF
axis in MPM. We demonstrate that miR-15/16 replace-
ment downregulates FGF/FGFRs and provide evi-
dence that inhibition of FGF/FGFR-dependent signals
contributes to the growth suppressive effects of miR-
15/16 mimics. Furthermore, we identified a vicious
cycle between FGF signaling and miR-15/16 downreg-
ulation, driving malignant growth. Combined inhibi-
tion of two independent miR-15/16 targets, FGFR1
and the Bcl-2, resulted in synergistic growth inhibition,
suggesting microRNA replacement as a novel therapy
for FGFR-dependent MPM and other FGFR-depen-
dent tumors.
2. Material and methods
2.1. Cell culture and cell lines
All cell lines were maintained in RPMI-1640 or
DMEM medium (Thermo Fisher, Waltham, MA,
USA) containing 10% heat-inactivated FBS in a
humidified atmosphere of 5% CO2 at 37 °C. Cell lines
were regularly checked for mycoplasma contamination
(MycoFluor, Thermo Fisher) and STR profiling was
used to confirm identity (GenePrint 10, Promega,
Madison, WI, USA) once per year. All used cell lines,
the histological MPM subtype they were derived from,
their standard growth medium as well as their source
are listed in Table S1.
2.2. MicroRNA mimics and siRNAs
MicroRNA mimics as well as validated negative con-
trol mimics (nc) were dissolved in ultrapure H2O and
transfected as described below. For siRNAs, a nontar-
geting control siRNA (c-81) was used. SiRNA specific
for RRM1 served as control for transfection efficacy.
All used microRNA mimics and siRNAs, their
sequences/IDs and sources are listed in Table S2.
2.3. Cytokines and drugs
Recombinant FGF2 or FGFR/Bcl-2 inhibitors were
directly added to cells at the indicated concentrations.
As control, equal amounts of solvent (PBS for FGF2,
DMSO for all inhibitors) were added. Treatments,
their targets and sources are summarized in Table S3.
2.4. Transfection with microRNA mimics and
siRNAs
Reverse transfection with microRNA mimics or siR-
NAs was carried out as per the pipetting scheme in
Table S4. First, mimics or siRNAs were diluted in
serum-free RPMI medium to the required concentra-
tions. Lipofectamine (RNAiMAX, Thermo Fisher)
was diluted 1 : 100 in serum-free medium. After at
least 5 minutes, appropriate volumes of lipofectamine
and diluted mimic/siRNA were mixed and incubated
for at least 20 minutes and up to 2 h at room temper-
ature. Meanwhile, cells were harvested, counted, and
diluted as required. Finally, the lipofectamine/RNA
mix was added into each well and cells were added,
gently mixed, and transferred to the incubator.
2.5. RNA isolation and RT-qPCR
Cells were transfected in 6-well plates (1.5 9 104 cells
per well) with microRNA mimics (5 nM) or siRNAs
(10 nM) according to the scheme in Table S4. After the
indicated time, RNA was isolated using TRIzol
(Thermo Fisher) according to the manufacturer’s
instructions and dissolved in ultrapure H2O.
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Concentration and purity of the RNA were measured
on a nanophotometer (Implen, Munich, Germany).
For the analysis of target genes, 500 ng RNA was
reverse-transcribed with Superscript III reverse tran-
scriptase (Thermo Fisher). To measure the expression
of microRNAs, 50 ng RNA was reverse-transcribed
using MultiScribe reverse transcriptase (Thermo
Fisher) and stem-loop RT primers specific for the
microRNA of interest. SYBR green- or TaqMan-based
real-time quantitative PCR was performed according
to the manufacturer’s instructions on an ABI-7500
(Applied Biosystems, Foster City, CA, USA) or ViiA7
(Thermo Fisher) thermocycler. 18S was used as a ref-
erence for mRNA, and RNU6B and miR-191 as refer-
ences for microRNA expression, respectively. All used
TaqMan microRNA assays are listed in Table S5. Pri-
mers and sequences for SYBR green-based PCR are in
Table S6. Relative levels of mRNAs or microRNAs
were calculated as previously described (Reid et al.,
2013) using the 2DDCq method (Livak and Sch-
mittgen, 2001).
2.6. Luciferase reporter assay
Fragments of the 30UTRs of FGF1, FGF2, FGF5,
FGF18, FGFR1, and FGFR4 containing binding sites
for miR-15a, miR-15b, and miR-16 were cloned from
SPC212 cDNA. Total RNA was reverse-transcribed
(MMLV RT kit, Promega) and fragments were ampli-
fied using AmpliTaq Gold 360 (Promega) with specific
forward and reverse primers (Table S7). PCR products
were first cloned into the TOPO TA vector (Thermo
Fisher) and then subcloned into the pSiCheck2 plas-
mid (Promega). The mutated FGFR1 constructs were
generated by site-directed mutagenesis. Briefly, specific,
completely overlapping primers harboring a mutation
in the microRNA binding site were designed
(Table S7) and a PCR was carried out using PfuUltra
II Fusion HS DNA Polymerase (Agilent, Santa Clara,
CA, USA) followed by DpnI (NEB, Ipswich, MA,
USA) digest. Sequences were confirmed by Sanger
sequencing carried out at the Ramaciotti Centre
(UNSW, Sydney). The resulting reporter constructs
(1 lg), together with microRNA mimics or controls
(5 nM), were used to transfect 2 9 105 cells in 6-well
plates. A dual luciferase assay (Promega) was carried
out as per the manufacturer’s protocol 48 h after
transfection.
2.7. Protein isolation and western blot
For protein analysis, 4 9 105 cells in T25 flasks were
transfected with 2.5 nM microRNA mimics. After
96 h, protein was isolated in lysis buffer (150 mM
NaCl, 50 mM HEPES, 10% glycerol, 1 mM EDTA,
0.5 mM Na3VO4, 10 mM NaF, 1% Triton X-100, and
1.5 mM MgCl2) and concentration was measured using
a Bradford protein assay (Bio-Rad, Hercules, CA,
USA). 20 lg of protein per lane was separated by
SDS/PAGE (precast, NuSep) and blotted onto PVDF
membranes. Immunodetection was performed using
antibodies against FGFR1 (D8E4 XP, #9740, Cell Sig-
naling; 1 : 1000) and FGFR4 (H-121, sc-9006, Santa
Cruz, Dallas, TX, USA; 1 : 1000). Beta-actin
(#A5441, Sigma, St. Louis, MO, USA; 1 : 10 000)
served as loading control.
2.8. Growth inhibition assay
Triplicate of 2.5 9 103 MPM cells were transfected
with microRNA mimics, siRNAs, or various combina-
tions as indicated and seeded in a 96-well plate with a
total volume of 120 lL per well. Usually, mimics were
used at final concentrations of 0.2 nM, 1 nM, and 5 nM
and siRNAs at 10 nM. In case of additional treatment
with cytokines or drugs, 80 lL of medium containing
the compound at the required concentrations or vehi-
cle was added to a total volume of 200 lL per well.
To test the effects of drugs alone, 2 9 103 cells per 96-
well in a volume of 100 lL medium were seeded in
triplicate. On the next day, cells were treated with
100 lL of medium containing drugs single or in com-
bination as indicated. At the indicated time points, the
medium was discarded and plates were frozen at
80 °C. For analysis, plates were thawed and 200 lL
lysis buffer (10 mM Tris/HCl pH = 8, 2.5 mM EDTA,
0.1% Triton X-100) containing SYBR green (10 0009,
Thermo Fisher, 1 : 8000) was added. Plates were incu-
bated overnight at 4 °C in the dark. Fluorescence was
measured at 485/520 nm on a FLUOstar OPTIMA
microplate reader (BMG Labtech, Offenburg, Ger-
many).
2.9. MTT assay
Triplicate of 2 9 103 cells in 100 lL medium were
seeded into a 96-well plate. On the next day, 100 lL of
medium containing treatments was added. DMSO was
used as solvent control. After 72 h, cell viability was
measured by MTT assay according to the manufactur-
ers’ protocol (EZ4U, Biomedica, Vienna, Austria).
2.10. Colony formation assay
Cells (2.5 9 103) were transfected with mimics in 96-
well plates as described above. On the next day, cells
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from each well were harvested and half transferred
into each of two wells of a 6-well plate, resulting in
approximately 1000–1500 cells per well, and returned
to the incubator. After 7–14 days, cells were fixed with
methanol/acetic acid (3 : 1) and clones were stained
with crystal violet and air-dried and pictures were
taken. For quantification, clones were destained in 2%
SDS, and absorbance was read at 562 nm.
2.11. Statistical analysis
If not stated otherwise, all data are presented as
means  SEM of at least three independent experi-
ments performed in triplicate. Statistical significance
between control and treatment groups was calculated
using Prism7 (GraphPad, San Diego, CA, USA) using
one-way ANOVA with Dunnett’s multiple comparison
test for comparison of multiple groups. Pearson’s cor-
relation was used to investigate correlations between
the effect of microRNAs re-expression on cell growth
and sensitivity to pharmacological FGFR inhibition.
A P-value <0.05 was considered statistically significant.
AUCs were calculated with Prism7. Combination
indices (CI values) were calculated using the COMPUSYN
software (CompuSyn Inc., Paramus, NJ, USA). Pre-
dicted values (PV) for additive effects represent the
arithmetic products of the % viability of each single
treatment.
3. Results
3.1. Downregulation of the microRNA-15/16
family corresponds with an upregulation of the
FGF axis in MPM cell lines
Recently, our work has shown hyperactivation of
FGF signals due to overexpression of FGFR1, FGF2,
and FGF18 in MPM (Schelch et al., 2014). As there
are no gene amplifications or mutations reported, we
reasoned that microRNAs might play a role in the
aberrant FGF/R expression. We used target prediction
(TargetScanHuman 7.1, Agarwal et al., 2015) and
found that the tumor-suppressive miR-15/16 micro-
RNA family, which is frequently downregulated in
tumors including MPM (Reid et al., 2013), is predicted
to target several members of the FGF axis.
To investigate the relationship between the miR-15/
16 family and the FGF axis, we first measured the
expression of miR-15a, miR-15b, and miR-16 as well
as several members of the FGF/FGFR family in a
panel of seven MPM cell lines (plus five drug-resistant
derivatives) via RT-qPCR. MeT-5A, a nonmalignant
transformed mesothelial cell line, was used as a
reference. We found a prominent overexpression of
FGFR1, FGF2, and FGF18 (Fig. 1A) as well as
reduced expression of the microRNAs miR-15a, 15b,
and 16 in the MPM cell lines compared with MeT-5A
(Fig. 1B).
3.2. The miR-15/16 family targets the FGF axis in
MPM
In order to directly assess the impact of the miR-15/16
family members on FGF/FGFR expression in MPM
cells and to validate the prediction of FGF/FGFRs as
miR-15/16 targets in MPM, we reintroduced each of
the three miRNAs into the MPM cell lines via trans-
fection with mimics and measured target gene expres-
sion via RT-qPCR. All three miRNA mimics led to
downregulation of the expression of FGFR1 and
FGFR4, which are both predicted targets of the
respective miRNAs. Among the ligands, FGF1,
FGF2, and FGF18 are predicted targets and all three
were also reduced upon mimic expression (Fig. 1C).
FGF5 is not a target of the miR-15/16 family and, as
expected, was not downregulated. Luciferase reporter
assays confirmed the direct interaction between miR-
15a, 15b, and 16 and their predicted target sites in the
30UTR of FGFR1 (FGFR1/1, FGFR1/2), FGFR4,
FGF1, FGF2, and FGF18, but no interaction with
FGF5 or mutated target sites of FGFR1/1 or FGFR1/
2 was found. (Fig. 1D). We also observed a downregu-
lation of FGFR1 on the protein level after transfection
with miRNA mimics (Fig. 1E). This was more pro-
nounced with miR-15a and miR-16, reflecting the
changes in the mRNA level. These findings establish
several FGF/FGFR members as experimentally vali-
dated targets of the miRNA 15/16 family in mesothe-
lioma.
3.3. Growth repression by miRNA mimics
correlates with sensitivity to FGFR1 inhibition in
MPM cells
In line with our previous findings, transfection with
miRNA mimics led to a dose-dependent growth
repression of MPM cells (Fig. 2A). In agreement with
the effects on target gene expression, miR-15b also
had the weakest impact on MPM cell growth. The
strongest effect was seen in MSTO, SPC212, and P31
cells, while VMC20, M38K, SPC111 as well as the
control mesothelial cell lines MeT-5A and LP9 were
only moderately affected. Restoration of miR-15/16
also dose dependently reduced the ability to form colo-
nies in MPM cells when plated at low density (Figs 2B
and C, S1).
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Fig. 1. The microRNAs 15a, 15b, and 16 are downregulated in mesothelioma cells and target several members of the FGF family.
Expression of (A) several members of the FGF axis and (B) the microRNA-15/16 family compared to MeT-5A, analyzed by RT-qPCR. (C)
Cells were transfected with microRNA mimics (5 nM) and target gene expression was checked after 24 h via RT-qPCR and compared with
noncoding (nc) control mimics. Each dot represents one cell line and is depicted as the mean of three independent experiments. (D)
Normalized percentage of luciferase activity (renilla/firefly ratio, RL/FL) 48 h after transfection with microRNA or control mimics (5 nM) in
SPC212 cells. (E) Immunoblot analysis of FGFR1 expression 96 h after transfection with microRNA or control mimics (2.5 nM). *P < 0.05,
**P < 0.01, ***P < 0.001; otherwise, P > 0.05.
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We previously reported that FGFR1 inhibition
reduces MPM tumor growth in vitro and in vivo
(Schelch et al., 2014). In our panel of MPM cell lines,
MTT assays using the small-molecule-specific FGFR1
inhibitor PD166866 showed a dose-dependent decrease
in cell viability reflecting the effects seen by miRNA
mimics (Fig. 2D). There was a significant correlation
(Pearson) between the effectiveness of growth repres-
sion by mimic expression and sensitivity to PD166866
(Fig. 2E). The fact that those cell lines which are sen-
sitive to miR-15/16 are also more responsive to
FGFR1 inhibition suggests that blockade of FGF/
FGFR-dependent growth/survival signals is an impor-
tant player in growth regulation by this microRNA
family.
3.4. Stimulation with FGF2 can rescue mimic-
induced growth repression of MPM cells at early
but not late time points
We reasoned that in MPM cells dependent on FGF
signals for cell growth and survival, growth suppres-
sion upon mimic-induced downregulation of FGFs
would be prevented by stimulation with exogenous
FGF2 as long as FGFRs are sufficiently expressed.
Therefore, to further characterize the interaction
between miR-15/16 and the FGF axis, we stimulated
the cells at two different time points: 24 and 96 h after
transfection. Indeed, FGF2 treatment 24 h after trans-
fection could reduce/prevent the growth inhibition
effects caused by mimics (Figs 3A and S2). In con-
trast, when added 96 h after transfection, FGF2 had
no effect on cell growth (Figs 3B and S2). This is most
likely explained by reduced FGFR1 protein at this late
time point as shown in Fig. 1E.
3.5. MicroRNAs targeting the FGF axis are
regulated by FGFR-mediated signals in a vicious
cycle
Our data suggest that one of the functions of the miR-
15/16 family is to keep FGF signals in check. As regu-
lation of growth signals often involves feedback loops
to maintain homeostasis, we next investigated whether
activated FGF signals would in turn enhance micro-
RNA expression. We determined the expression of
miR-15a, miR-15b, miR-16, and their respective pre-
cursor pri-miRs via Taqman-based RT-qPCR after 24-
h stimulation with recombinant FGF2 and found fur-
ther downregulation of miR-15/16 in the majority of
cell lines (Fig. 4A, Table S8). However, there was no
significant correlation between expression changes and
sensitivity to mimics/FGFR inhibition (data not
shown). In addition to miR-15a, -15b, and -16, miR-
195, and miR-424—additional members of this family
—as well other microRNAs predicted to target various
members of the FGF axis—miR-23a, miR-24, and
miR-223—were also downregulated upon FGF path-
way activation. In contrast, miR-93, miR-103, miR-
137, and miR-193a-3p, which are not involved in the
regulation of the FGF axis, remained largely
unchanged (Fig. 4B, Table S8). These data suggest
that a feed-forward cycle is operational in the mutual
regulation between the miR-15/16 family and the FGF
axis in MPM cells. Once triggered, this feed-forward
loop could result in a vicious cycle contributing to
enhanced cell growth in MPM. This model would sug-
gest that, conversely, inhibition of FGF signals could
partially rescue miR-15/16 expression. Therefore, we
treated the three sensitive cell lines with the FGFR1
inhibitor PD166866 as well as the multikinase inhibitor
ponatinib, which inhibits FGFR1-4, Abl, PDGFRA,
and Src, and assessed the expression of miR-15/16.
Indeed, after 48 h, we observed with both treatments
an upregulation of miR-15a, -15b, and -16 (Fig. 4C).
3.6. Competition between microRNA restoration
and FGFR inhibition confirms interaction
between miR-15/16 and the FGF axis
As our data suggest that mutual regulation between
miR-15/16 and FGF signals drives enhanced growth
of MPM cells, interference with either one or both
mechanisms could prove therapeutically beneficial.
Indeed, we have previously demonstrated that restora-
tion of miR-16 is feasible in MPM models and results
in growth suppression in vitro and in vivo (Reid et al.,
2013) and several groups including our own have
established FGFR inhibition as viable anti-MPM
strategy (Blackwell et al., 2016; Marek et al., 2014;
Schelch et al., 2014). Thus, we tested the effect of com-
bining microRNA replacement with pharmacological
FGFR inhibition. The combination of mimic expres-
sion with the FGFR1 inhibitor PD166866 reached a
higher total growth inhibition compared with each
treatment alone. However, with higher doses of mim-
ics, the combinations showed reduced effects compared
with the single treatments, indicating target competi-
tion (Fig. 5A). Comparable results, showing effects
weaker than the predicted value (PV, indicated as
white ticks within the black bars) of additive interac-
tions, were obtained when we combined miRNA mim-
ics with siRNA against FGFR1, FGFR4, or a
combination of both (Figs 5B, S3 and S4).
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3.7. Combined inhibition of the miR-15/16 targets
FGFR1 and Bcl-2 has synergistic effects in MPM
cells
We reasoned that inhibition of two independent tar-
gets of miR-15/16 might avoid the target competition
seen in Fig. 5. A well-established target of the miR-15/
16 family is the anti-apoptotic protein Bcl-2, for which
both the clinically relevant specific inhibitor venetoclax
and the broadly active Bcl-2 family inhibitor obatoclax
are available. First, we confirmed the downregulation
of Bcl-2 upon transfection with microRNA mimics in
our panel of cell lines via RT-qPCR. As expected, Bcl-
2 levels were reduced in all cell lines (Fig. 6A). There-
fore, we next tested the FGFR1 inhibitor PD166866 as
well as the multikinase inhibitor ponatinib in combina-
tion with venetoclax and obatoclax. Used as single
agents, obatoclax was highly effective in the nanomo-
lar range; venetoclax, however, required much higher
concentrations to inhibit growth in MPM cells
(Fig. 6B). Importantly, in combination with low-dose
FGFR inhibitors, we found enhanced effects of both
obatoclax and venetoclax. The combination of obato-
clax and ponatinib showed synergistic activity in all
three cell lines tested, with combination indices (CI)
below 1, especially at the lower concentrations
(Fig. 6C). In the other combination settings, where
calculation of CI values was not possible, effects stron-
ger than the predicted value (PV, indicated as red
bars) of additive interactions were observed at concen-
trations of 1 lM PD166866 or 100 nM ponatinib in
combination with 50 nM obatoclax or 10 lM veneto-
clax (Figs 6C and S5).
4. Discussion
The translation of specific molecularly targeted
approaches into clinical practice, often in combination
with conventional chemo- or radiotherapy, has become
a promising strategy, which is currently improving the
treatment for various other cancers (Iams et al., 2017;
Lemjabbar-Alaoui et al., 2015). However, MPM
remains an exception. Apart from a modest increase in
median survival by the addition of bevacizumab to the
standard pemetrexed/platinum combination, this
asbestos-related cancer (Zalcman et al., 2015), with
increasing worldwide incidence, continues to be
renowned for its treatment resistance. Therefore, novel
insight into the molecular basis of treatment resistance
and more effective treatment strategies are urgently
needed. Our previous work characterized the FGF axis
as a potent malignant driver in MPM, and we also
described the tumor-suppressive role of the miR-15/16
family, which is frequently downregulated in MPM
(Reid et al., 2013; Schelch et al., 2014).
So far, the tumor suppressor function of miR-15/16,
which targets important drivers of malignant growth
such as FGF2 and the anti-apoptotic protein Bcl-2
(He et al., 2016; Willimott and Wagner, 2010), has
been well established in various tumor types including
prostate, lung, ovarian, and MPM (Bandi et al., 2009;
Bhattacharya et al., 2009; Bonci et al., 2008; Reid
et al., 2013). We demonstrate here that several mem-
bers of the FGF axis (FGFR1, FGFR4, FGF1,
FGF2, and FGF18) are prominent miR-15/16 targets,
downregulated in MPM cells upon microRNA restora-
tion via mimics.
The loss of post-transcriptional control of the FGF
axis due to downregulation of microRNAs is a poten-
tial mechanism underlying the high expression of the
FGF axis in tumors such as MPM, which do not show
gene amplifications or mutations (Marek et al., 2014).
However, a lack of a significant correlation between
basal FGF/R levels and miR-15/16 expression suggests
that the levels of this microRNA family contribute to,
but do not completely control, regulation of FGF/R
expression. Besides miR-15/16, other microRNAs have
also been shown to impact on FGF signals in malig-
nant and nonmalignant diseases, including miR-99a,
miR-214, or miR-216 (Jiang et al., 2014; Wang et al.,
2008, 2013). Interestingly, miR-99a was found at lower
levels in MPM samples compared with normal pleura
(Andersen et al., 2014) and differentially expressed
between epithelioid and sarcomatoid tumors (Pass
et al., 2010). Similarly, miR-214 was shown to be
downregulated in MPM samples compared with con-
trols in two independent studies (Amatya et al., 2016;
Balatti et al., 2011). In addition, we found that FGF
signaling suppressed the expression of miR-23a and
miR-223, both of which are altered in MPM and
Fig. 2. Growth repression by microRNA mimics correlates with sensitivity to FGFR1 inhibition. (A) Growth inhibition determined by SYBR
green staining 72 h after transfection with mimics compared with noncoding control (nc). (B) Quantification of colony formation assays of
the three sensitive cell lines after transfection with mimics as indicated. (C) Representative colony formation pictures of MSTO cells
transfected with 5 nM microRNA or control mimics as indicated. (D) Dose–response curves of MPM cell lines 72 h after treatment with
PD166866 or DMSO (co), determined by MTT assay. (E) Growth inhibition shown as area under curve (AUC) of mimics (5 nM) in correlation
(Pearson) effects of PD166866, calculated from MTT dose–response curves in E. Each dot represents one cell line. *P < 0.05, **P < 0.01,
***P < 0.001; otherwise, P > 0.05.
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predicted to target components of the FGF axis (Bir-
nie et al., 2015; Cheng et al., 2013).
Previously, high levels of both amplified and nonam-
plified FGFRs have been linked to response to FGFR
inhibition in various cancers (Goke et al., 2015;
Nakanishi et al., 2014; Wynes et al., 2014; Zhang
et al., 2014). In accordance with this, we have recently
shown that nonmalignant mesothelial cells express
much lower levels of FGF/R and are more resistant to
FGFR inhibition than MPM cells (Schelch et al.,
2014). However, among the MPM cell lines tested, nei-
ther FGF/R nor miR-15/16 basal expression correlated
with sensitivity to FGFR inhibition or mimics. Also,
comparable to MeT-5A, some MPM cell lines did not
respond to growth inhibition. This suggests that the
actual signals which trigger cell proliferation and sur-
vival and therefore the extent of dependency on the
FGF axis are controlled by a combination of multiple
factors including transcriptional and translational reg-
ulation and other effectors acting downstream of the
FGF receptors. MicroRNAs targeting specific compo-
nents of the FGF family represent one part of this reg-
ulatory system, which is supported by effects of target
competition when we combined microRNA mimics
with FGFR inhibitors. Also, it is well known that the
FGF axis is part of a complex signaling network,
which interacts with numerous other pathways and is
influenced by various feedback and feed-forward loops
(Ornitz and Itoh, 2001). We have uncovered a vicious
cycle in MPM where FGF signaling is capable of
downregulating the miR-15/16 family and other FGF/
R-targeting microRNAs, thereby further driving their
growth-promoting effects by inhibiting their own
microRNA-mediated post-transcriptional regulation.
The involvement of the same tumor suppressor
microRNAs in the regulation of multiple cancer-
related signaling pathways highlights the potential of
microRNA mimics as novel cancer treatment
approach. In addition, it is unlikely that microRNA-
based therapy is negatively affected by mutation-
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induced resistance usually occurring with tyrosine
kinase inhibitors. MicroRNA replacement has been
evaluated in preclinical and clinical studies (Bader,
2012; Liang et al., 2016; Reid et al., 2013; Takeshita
et al., 2010). In MPM, a miR-16-based mimic has
shown early signs of clinical activity (Kao et al., 2015).
As the underexpression/loss of members of the miR-
15/16 family is not a unique characteristic of MPM
and considering the important role of the FGF axis in
tumor development and progression, it is more than
likely that the deregulation of FGF signals also con-
tributes to the tumor-promoting effects of miR-15/16
loss in other tumor types. Therefore, the miR-16 sup-
pletion approach needs further investigation for
tumors characterized with mutated or dysregulated
FGF signaling.
We demonstrate here that selecting microRNA target
proteins which (a) have a well-documented role in driv-
ing malignant growth and (b) can be targeted by phar-
macological inhibition represents a rational approach
for combination treatment in MPM. This approach
enabled us to identify that FGFR1 and Bcl-2 represent
novel synergistic treatment targets in MPM. Multiple
members of the miR-15/16 family may be targeted with
microRNA mimics, whereas FGFRs and Bcl-2 have the
advantage of being druggable. FGFR inhibition has
shown promising effects in various preclinical studies
(Dey et al., 2010; Maruyama-Takahashi et al., 2008;
Metzner et al., 2011; Pattarozzi et al., 2017; Qing et al.,
2009; Schelch et al., 2014) and is currently being tested
in patients with solid tumors, especially in those with
known FGFR overexpression or genomic alterations
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(Katoh and Nakagama, 2014). In mesothelioma, a phase
lll study using the multi-RTK inhibitor nintedanib
(NCT01907100) and a phase lb trial using the FGFR
ligand trap GSK3052230 in combination with first-line
chemotherapy (NCT01868022) are ongoing. Similarly,
inhibition of Bcl-2 also showed promising effects in vari-
ous cancers including MPM (Hoda et al., 2016; Li et al.,
2008; Schwartz et al., 2016; Xiong et al., 2016). Other
combined treatment approaches have been tested in
MPM (Kanteti et al., 2014; Ou et al., 2016), and a trial
of FAK and PD1 inhibition (NCT02758587) is ongoing.
With the lack of targetable mutations in MPM, novel
treatments focusing on gene expression and genomic
alterations are gaining increasing attention. For exam-
ple, a trial of the EZH2 inhibitor in the context of BAP1
loss-of-function mutation (NCT02860286) is currently
recruiting. Similarly, our characterization of the impact
of microRNA expression changes on MPM biology led
us to identify the synergistic effect of combining inhibi-
tors of FGFR1 and Bcl-2, two independent targets of
the miR-15/16 pathway. With the limited progress in
MPM treatment over the last decade, continuing use of
alternative approaches for the identification of novel
MPM treatment targets will be needed to improve the
outlook for patients.
In conclusion, our study suggests that loss of the
miR-15/16 family plays a role in the overexpression of
the FGF axis in MPM. We identified a vicious cycle of
malignant growth between FGF signals and miR-15/16
and show that cells which are more sensitive to FGFR
inhibition also respond better to microRNA mimics,
providing evidence for microRNA replacement as an
alternative therapeutic approach in MPM and other
tumors harboring FGF/R mutations or amplifications.
Furthermore, we demonstrate that combined inhibition
of two miR-15/16 targets, FGFR1 and Bcl-2, has syner-
gistic effects on tumor cell growth encouraging further
consideration as novel combination strategy in MPM.
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RNA mimics or non-coding control.
Fig. S2. Growth inhibition assays of P31 and MSTO
cells after transfection with mimics in combination
with FGF2 treatment.
Fig. S3. Target gene and protein expression analysis
after transfection with siRNAs via qPCR or western
blot.
Fig. S4. Growth inhibition assays of P31 and MSTO
cells 72 h after transfection with microRNA mimics
and/or siRNAs or respective controls.
Fig. S5. Growth inhibition assays of SPC212, MSTO
and P31 cells 72 h after treatment with PD166866 (PD)
or ponatinib (Pon) in combination with obatoclax or
venetoclax, or respective controls, at the indicated doses.
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